Your AI-Trained Oncology Knowledge Connection!

Howard A. Burris III, MD

home / authors / howard-burris-iii-md

Articles

Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.

Howard A. Burris, MD, Talks QOL With Durvalumab/Chemo in Advanced Biliary Tract Cancer From TOPAZ-1 Trial

July 13th 2022

Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes data that were presented at 2022 ASCO.

Gemcitabine, Paclitaxel, and Carboplatin for Advanced Non–Small-Cell Lung Cancer

F. Anthony Greco, MD;Howard A. Burris III, MD;John D. Hainsworth, MD

July 1st 2000

The purpose of this study was to evaluate the combination of gemcitabine (Gemzar), paclitaxel (Taxol), and carboplatin (Paraplatin) in patients with advanced non–small-cell lung cancer (NSCLC). Previously untreated

Docetaxel in Combination With Fluorouracil for Advanced Solid Tumors

Howard A. Burris III, MD

August 1st 1997

The results from preclinical studies using murine tumor models show that the combination of docetaxel (Taxotere) and fluorouracil (5-FU) is highly synergistic. Phase I studies in patients

Docetaxel in Combination With Flourouracil: Study Design and Preliminary Results

Eric Rowinsky, MD;Lon Smith, MD;Gladys Rodriguez, MD;Ronald Drengler, MD;Daniel D. Von Hoff, MD;Nancy Peacock, MD;Cheryl Aylesworth, MD;Howard A. Burris III, MD;Peter Ravdin, MD, PhD;Robert Bellet, MD

June 1st 1997

The relatively recent introduction of a new class of chemotherapeutic agents--the taxoids--has raised hope of improved survival for patients with advanced or metastatic cancer. Following encouraging preclinical results of taxoid combinations, this phase I, nonrandomized trial was designed to evaluate a 1-hour intravenous infusion of docetaxel (Taxotere) on day 1 combined with fluorouracil (5-FU) as a daily intravenous bolus for 5 consecutive days.